Not a good buy right now for an impatient investor: no proprietary buy signals, momentum is slightly bearish, and near-term pattern odds don’t favor upside.
Best stance is to wait; if forced to act now, the risk/reward is not attractive unless price reclaims resistance (~2.41) with improving momentum.
Key levels: downside risk toward ~2.07 (S1) / ~1.96 (S2); upside is capped near ~2.41 (R1) then ~2.52 (R2).
Technical Analysis
Trend/momentum: MACD histogram is negative (-0.0342) but contracting, suggesting bearish momentum is easing (potential stabilization, not a confirmed reversal).
RSI(6) ~47: neutral—no oversold bounce signal and no strong bullish momentum.
Moving averages: converging MAs imply consolidation/indecision rather than a clean uptrend.
Pivot framework: Price (2.21) is below pivot (2.24), which is mildly bearish; needs to retake/hold above 2.24 then break 2.41 to look like a momentum buy.
Probabilistic pattern read: similar-pattern stats imply modest upside next day/week but slightly negative expected move over the next month (-1.36%), which is not ideal for chasing now.
Positive Catalysts
holds.
Neutral/Negative Catalysts
and still under nearby resistance (2.41), keeping the setup “range/weak” rather than “breakout.”
Financial Performance
Latest quarter: 2026/Q1.
Revenue: $100K, reported as 0.00% YoY change (essentially flat/immaterial scale).
Net income: -$5.72M, improved 43.39% YoY (loss narrowed).
Overall: still loss-making with very small revenue base; fundamentals do not currently support an “impatient buy now” posture.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
[2025-12-18] LifeSci Capital initiated iBio at Outperform with a $5 price target (bullish).
Another item provided ([2026-01-20] Piper Sandler) discusses ImmunityBio rather than iBio, so it should not be treated as a reliable IBIO rating/target update.
Wall Street pro view (based on usable data): Pros—bullish initiation with sizable upside implied vs. current price. Cons—coverage is sparse/limited here, and there’s no recent wave of upgrades/target raises confirmed specifically for IBIO.
Wall Street analysts forecast IBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBIO is 4.75 USD with a low forecast of 2 USD and a high forecast of 6 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast IBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBIO is 4.75 USD with a low forecast of 2 USD and a high forecast of 6 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.150
Low
2
Averages
4.75
High
6
Current: 2.150
Low
2
Averages
4.75
High
6
Piper Sandler
Overweight
upgrade
$5 -> $7
AI Analysis
2026-01-20
Reason
Piper Sandler
Price Target
$5 -> $7
AI Analysis
2026-01-20
upgrade
Overweight
Reason
Piper Sandler raised the firm's price target on ImmunityBio to $7 from $5 and keeps an Overweight rating on the shares. The firm notes U.S. ANKTIVA Net revenues grew about 700% to $113M in 2025, and it now projects $180M in 2026. Based on strong interim data, Piper is confident positive QUILT-2.005 data in Q4 2026 could lead to ANKTIVA label expansion in 2027.
LifeSci Capital
initiated
$5
2025-12-18
Reason
LifeSci Capital
Price Target
$5
2025-12-18
initiated
Reason
LifeSci Capital initiated coverage of iBio with an Outperform rating and $5 price target.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IBIO
